Celgene (CELG) Says OTEZLA Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
